478 results about "Mannitol" patented technology

Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.

The application relates to an organic-inorganic compound fertilizer containing functional microorganisms and a production method thereof, and relates to the technical field of fertilizers. The fertilizer comprises an inorganic core layer, an organic coating layer and a functional microorganism outer layer. The functional microorganism outer layer comprises the following components in mass fractions: 10-15 parts of compound functional microorganisms, 5-10 parts of synergistic growth-promoting microorganisms, 2-3 parts of trehalose, 1-2 parts of mannitol, 10-15 parts of sodium alginate, 8-10 parts of chitosan, 2-4 parts of yeast extract and 30-40 parts of modified active carbon carriers. The production method comprises the following steps: preparing the inorganic core layer, preheating the inorganic core layer, spraying the organic coating layer material to coat the surface, and obtaining a preliminary product with the organic coating layer; coating the functional microorganism outer layer material on the surface of the organic coating layer of the preliminary product, low-temperature drying and screening, and obtaining the organic-inorganic compound fertilizer containing the functional microorganisms. The application has the effects of improving the slow-release effect of the fertilizer and the survival rate of the microorganisms.

The invention belongs to the field of biology, and discloses a CRISPR / Cas12a freeze-dried microsphere, which is characterized in that the CRISPR / Cas12a freeze-dried microsphere is obtained by freeze-drying the following raw materials: enzyme-free water, 10 * HOLMES Buffer for Cas12a, an RNA enzyme inhibitor, CRISPR / Cas12a protein, crRNA, an upstream primer F, a downstream primer R, a fluorescent probe Reporter and a freeze-drying protective additive; the CRISPR / Cas12a protein is an LbaCas12a protein, and the CRISPR / Cas12a protein is a Cas12a protein; the freeze-drying protective agent is prepared from mannitol, trehalose, polyethylene glycol, glucan and BSA (Bovine Serum Albumin). By further optimizing a freeze-drying protective agent, freeze-drying microballing of a CRISPR / Cas12a system is achieved, the freeze-drying microballing can be matched with RPA constant-temperature amplification double microballing, and detection is conducted through a one-step method. Meanwhile, the invention further discloses a three-microsphere detection system, application and a kit.

The invention provides a battery and an electric device. A positive plate comprises a positive active material, and the positive active material is doped and / or coated with a lanthanum element; the surface of the diaphragm is coated with a ceramic coating; the electrolyte comprises a first solvent, a second solvent, a first additive and a second additive; the first solvent comprises a cyclic carbonate compound, the second solvent comprises a chain fluorosulfonamide compound, the first additive comprises mannitol carbonate sulfate, and the second additive comprises succinonitrile; the lanthanum element is doped / coated on the positive active material, so that the release of lattice oxygen at high voltage or high temperature can be effectively inhibited, and the exothermic reaction activity at the thermal runaway initial temperature is reduced; the first additive and the second additive in the electrolyte respectively form a compact CEI film and an SEI film with high thermal stability on the surfaces of the positive electrode and the negative electrode; the diaphragm ceramic coating provides a physical barrier, the thermal shrinkage temperature of the diaphragm is increased, and internal short circuit is prevented.

The invention discloses a low-temperature vacuum microwave freeze-dried sinomenine hydrochloride preparation and a preparation method thereof in the technical field of pharmaceutical preparations, and solves the problems of long drying time, high energy consumption and poor product stability in the traditional freeze-drying technology. A vacuum microwave collaborative freeze-drying technology is adopted, microwave internal heating is achieved through a 2.45 GHz magnetron microwave generator and a rectangular waveguide tube under the conditions that the vacuum degree is 20-30 Pa and the plate layer temperature ranges from-40 DEG C to-35 DEG C, the microwave power density in the primary drying stage ranges from 0.3 W / g to 0.5 W / g, the microwave power density in the secondary drying stage ranges from 0.1 W / g to 0.3 W / g, and collaborative control over the microwave power, the vacuum degree, the temperature and the time is achieved in cooperation with a quaternary coupling precise control system. The preparation contains 50 mg of sinomenine hydrochloride, 100 mg of mannitol and 10 mg of sodium carboxymethyl cellulose grafted modified polyvinylpyrrolidone, the residual moisture is controlled to be 0.4-0.6%, the activity retention rate is 94-96%, and the drying time is shortened to 12-16 hours.

The invention relates to the technical field of purification of fine chemical intermediates, in particular to a purification method of a mannitol carbonate sulfate preparation process intermediate, which comprises the following steps: S1, synthesizing diacetone-D-mannitol; s2, preparing an organic solution containing solids; s3, performing deprotection reaction to prepare a solid crude product; s4, removing unreacted solids; s5, extracting and separating by-product solids; and S6, purifying the target product solid and recovering mannitol. Through system separation and multi-component recovery, preparation of a high-purity product and cyclic utilization of unreacted substances, byproducts and raw materials are realized, the yield is remarkably improved, the cost is reduced, and the quality of a final product is guaranteed.

The invention belongs to the technical field of chemical detection, and particularly relates to a method for detecting the content of boron in soil and sediment, which comprises the following detection methods: S1, weighing a sample and putting the sample into a digestion tank; s2, adding a digestion solution into the digestion tank; s3, after uniform stirring, putting the digestion tank into a microwave digestion instrument for microwave digestion; s4, after digestion is completed, closing the microwave digestion instrument, and after the digestion tank is cooled to the room temperature, filtering to remove precipitates; s5, transferring the digestion solution into a volumetric flask, and fixing the volume for subsequent analysis; and S6, analyzing the digestion solution by using ICP-OES / MS (Inductively Coupled Plasma-Optical Emission According to the method for detecting the boron content in the soil and the sediment, ammonium fluoride is used for replacing hydrofluoric acid in boron detection of the soil and the sediment, use of toxic reagents is reduced, mannitol is added, a stable complex is formed by mannitol and boron, and the recovery rate of boron is increased.

The invention discloses stem cell freeze-dried powder for promoting skin healing and a preparation method of the stem cell freeze-dried powder. The freeze-dried powder comprises an effective component, a freeze-drying protective agent group and a polymer protective agent group, the effective component is umbilical cord mesenchymal stem cell conditioned medium freeze-dried supernatant, the protective agent group is selected from one or more of cane sugar, trehalose, lactose and mannitol, and the polymer protective agent group is selected from one or more of polyvinylpyrrolidone (PVP) and glucan. The preparation method comprises the following steps: collection of a conditioned culture medium, preparation of a freeze-drying protective agent solution, mixing treatment, low-temperature pre-freezing and freeze-drying, collection and packaging of freeze-dried powder and the like. The method can effectively retain stem cell-derived active factors and enhance the stability and redissolvability of the freeze-dried powder, and is suitable for skin wound repair, regenerative medicine and other scenes.

The invention discloses a melatonin rapidly disintegrating oral tablet and a preparation method thereof, and the melatonin rapidly disintegrating oral tablet is prepared from the following raw materials in parts by weight: 40 to 55 parts of mannitol, 3 to 6 parts of cross-linked povidone, 0.5 to 2.0 parts of povidone, 2 to 6 parts of melatonin, 30 to 45 parts of filler and 0.3 to 1.5 parts of lubricant. Wherein the mannitol is beta-crystal form mannitol. According to the invention, mannitol of a limited type is matched with raw materials such as polyvinylpolypyrrolidone, and meanwhile, a specific mixing and tabletting process is adopted, so that the tablet can be rapidly disintegrated in an oral cavity while the hardness of the tablet is maintained, the bioavailability is high, and the requirements of the health food field on taking convenience, effectiveness and industrial production can be met.

Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.

The invention relates to the field of veterinary drugs, in particular to a veterinary GS-441524 tablet and a preparation method thereof. In the application, the GS-441524 raw material medicine, the filling agent, the disintegrating agent, the lubricating agent and the stabilizing agent are used as raw materials, the combination of mannitol and microcrystalline cellulose is selected as the filling agent, and coating is performed, so that the novel veterinary GS-441524 tablet is prepared, the medicine loss caused by thermal decomposition of API in the tabletting process is reduced, and the uniformity and the stability of the medicine in the tablet are improved.

The invention provides an anti-aging composition containing schizophyllan, a medical beauty injection preparation and application of the anti-aging composition and the medical beauty injection preparation, the anti-aging composition comprises hyaluronic acid or salt of the hyaluronic acid, the schizophyllan and mannitol, and the mass ratio of the hyaluronic acid or the salt of the hyaluronic acid to the schizophyllan to the mannitol is (0.2-3): (0.01-0.5): (0.5-5). According to the anti-aging composition disclosed by the invention, through the multi-component synergistic effect of the schizophyllatin, the hyaluronic acid or the salt thereof and the mannitol, the proliferation activity of fibroblasts can be remarkably improved, and the synthesis and expression of collagen can be efficiently promoted, so that the depth and the quantity of skin wrinkles are effectively improved, and the compactness and the elasticity of the skin are remarkably enhanced; the comprehensive skin rejuvenation effect is realized.

The invention provides a leavening agent and a preparation method thereof, and belongs to the technical field of leavening agents. According to the scheme, an efficient fermentation system is constructed through the synergistic effect of bacillus amyloliquefaciens, bacillus licheniformis, lactobacillus plantarum and saccharomyces cerevisiae, in the initial stage, the bacillus amyloliquefaciens secretes amylase and phytase degradation substrates, and conditions are created for the saccharomyces cerevisiae to metabolize monosaccharide to generate flavor substances and vitamins; in the middle stage, bacillus licheniformis decomposes protein to release amino acid, lactobacillus plantarum regulates pH through lactic acid metabolism to inhibit infectious microbes, and a multi-layer encapsulated compound enzyme preparation is introduced to synergistically degrade a complex substrate; in the later stage, fructooligosaccharide in the prebiotics-buffer stabilizer promotes proliferation of probiotics, mannitol and chitosan protect the activity of thalli and the function of metabolic enzymes, and the fermentation environment is stabilized; according to the whole system, the functionality, the environmental adaptability and the storage stability of the leavening agent are improved through flora synergistic metabolism, dynamic fermentation condition control and the action of the multifunctional additive, and the diversified requirements in industrial production are met.

The invention discloses preparation and application of a rabies virus G protein mRNA vaccine freeze-drying preparation, and relates to the field of veterinary biological products. According to the invention, rabies virus G protein mRNA is prepared on a large scale through an in-vitro transcription technology, and an mRNA-LNP (lipid nanoparticle) delivery system is successfully constructed by adopting a microfluidic encapsulation process. Through freeze-drying protective agent formula screening (including cane sugar, trehalose and mannitol) and freeze-drying procedure parameter optimization (including pre-freezing temperature, main drying rate and secondary drying residual moisture control), the freeze-dried mRNA vaccine preparation which can stably exist under the condition of 4 DEG C is finally obtained.

The invention provides a multilayer lutein ester liposome as well as a preparation method and application thereof, and belongs to the field of food processing. The multi-layer lutein ester liposome is prepared from the following raw materials: 30 to 50 parts of lutein ester, 40 to 60 parts of soybean phosphatidylcholine, 5 to 20 parts of cholesterol, 10 to 25 parts of starch sodium octenylsuccinate, 20 to 40 parts of trehalose, 15 to 30 parts of mannitol, 4 to 10 parts of phosphatidyl glycerol, 1 to 2 parts of vitamin E acetate and 1 to 2 parts of ascorbyl palmitate. According to the present invention, through the specific food-grade raw material composition and the accurate ratio relationship, the comprehensive delivery system is constructed for the highly hydrophobic and unstable lutein ester, and the system synchronously achieves the high encapsulation efficiency, the excellent stability, the good water dispersibility and the slow release function.

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The invention discloses afatinib tablets with high stability and rapid dissolution characteristics and a preparation method of the afatinib tablets, and belongs to the technical field of pharmaceutical preparations. In order to solve the problems that the dissolution rate is reduced and related substances are increased due to moisture absorption during the storage period of the existing afatinib tablets, afatinib dimaleate (crystal form A, D90 is 45-55m, and BET specific surface area is 2500-3000 m / kg) with a specific crystal form and particle size is adopted as a core and is compatible with an anhydrous crystal form auxiliary material (such as spray-dried mannitol), and the afatinib tablets are prepared into the afatinib tablets. Preparing a tablet core through dry granulation and a strict humidity control process, and then applying a damp-proof film coating. According to the scheme, the influence of water on the medicine is systematically blocked, the dissolution rate of the tablet in various dissolution media within 15 minutes is ensured to be greater than or equal to 85%, the dissolution rate is reduced by less than or equal to 5% after an accelerated test, the increase of related substances is obviously lower than that of a reference preparation, and the afatinib tablet with excellent dissolution performance and long-term stability is provided for clinic.

The application relates to the technical field of cough-relieving medicines, and discloses a high-efficiency cough-relieving loquat particle composition which is composed of the following components in parts by weight: loquat leaf extract 30-40 parts; white front extract 10-15 parts; platycodon grandiflorum extract 6-10 parts; white mulberry bark extract 18-25 parts; stemona sessiliflora extract 7-10 parts; menthol 0.1-0.5 part; polyethylene glycol 2-5 parts; mannitol 8-12 parts; ethyl cellulose 3-6 parts; hydroxypropyl methyl cellulose 1-3 parts; phosphatidylcholine 1-3 parts; polysorbate 80 1-3 parts; cross-linked sodium carboxymethyl cellulose 4-6 parts; and sucrose 40-60 parts. The double dispersion system combining the immediate-release component and the sustained-release component is adopted, the solubility and the initial release speed of the traditional Chinese medicine extract are remarkably improved through the addition of polyethylene glycol and mannitol, and the technical effect that the drug effect appearing time is remarkably shortened is achieved. Compared with the technical scheme relying on only a single release mode in the prior art, the deficiency that the drug effect is slow and the symptoms of the patient cannot be timely relieved is solved.

The invention discloses a preparation method of mannityl nicotinate impurities, which comprises the following steps: by taking nicotinic acid as an initial raw material, reacting the nicotinic acid with carbonyl diimidazole to generate pyridine-3-carbonyl-imidazole, esterifying with mannitol, and refining and purifying with a mixed solvent to prepare the mannityl nicotinate impurities. The purity of the mannitol nicotinate prepared by the method is not lower than 99%, and the preparation method is simple to operate, simple in post-treatment and suitable for industrial production.

The invention discloses a pharmaceutical composition for improving liver dysfunction, the pharmaceutical composition comprises a tablet core and a coating film, the tablet core comprises 30-40 parts of mono-ammonium glycyrrhizinate (20-30 parts by weight of glycyrrhizin), 20-30 parts of glycine, 20-30 parts of methionine, 55-65 parts of a filler, 2-10 parts of a disintegrating agent, 1-10 parts of an adhesive and 1-10 parts of a lubricant, and the coating film is a gastric soluble film coating; wherein the filling agent is formed by compounding lactose, microcrystalline cellulose, calcium carbonate, calcium hydrophosphate and mannitol, the mass ratio of the lactose to the microcrystalline cellulose to the calcium carbonate to the calcium hydrophosphate to the mannitol is (1-24): (1-35): (1-25): (1-9): (1-9), and the pharmaceutical composition for improving liver dysfunction has good dissolution and stability.

The invention belongs to the technical field of high polymer material additives, and particularly relates to a multifunctional additive, a synthesis method thereof and application of the multifunctional additive in PVC (polyvinyl chloride) processing. Modified mannitol and binary acid are used as raw materials for esterification reaction to obtain a product A, the product A and yttrium salt are mixed for reaction to obtain a product B, and the product B and cinnamyl ethyl methacrylate are mixed for free radical reaction to obtain the multifunctional additive. The multifunctional auxiliary agent can be used as a heat stabilizer to improve the thermal decomposition temperature of PVC, can also be used as a light stabilizer to reduce the influence of illumination on PVC, and can be well applied to PVC processing.

The invention discloses a synthesis method of mannitol carbonate sulfate, and belongs to the technical field of organic synthesis. The synthesis method provided by the invention comprises the following steps: reacting 1, 3, 4, 6-tetrachloro-2, 5-hexanediol with chlorosulfonic acid in the presence of an acid-binding agent to obtain an intermediate solution as shown in a formula (II); formula (II); and mixing the intermediate solution as shown in the formula (II) with anhydrous carbonate, heating to a first set temperature for reaction, and then heating to a second set temperature for reaction in the presence of a phase transfer catalyst to obtain the mannitol carbonic sulfate. The whole process route is short, the yield is high, and the total yield of two steps reaches 88% or above; meanwhile, few by-products are generated, the purification difficulty is low, the reaction time is short, few hazardous wastes are generated, operation is easy and convenient, and industrial large-scale production is facilitated.

The invention relates to high-stability amoxicillin powder for livestock. 100 kg of the amoxicillin powder mainly comprises the following raw materials by weight: 10 to 30 kg of amoxicillin, 2.5 to 7.5 kg of potassium clavulanate, 0.6 to 0.7 kg of a hydroxypropyl-beta-cyclodextrin-baicalin and chlorogenic acid compound inclusion body, 1.8 to 2.4 kg of citric acid and calcium carbonate controlled release microspheres, 23.7 to 45 kg of oat beta-glucan, 18 to 25 kg of pre-gelatinized cassava starch, 3 to 4 kg of mannitol, 8 to 12.7 kg of silanized microcrystalline cellulose, and the balance of water. The coating comprises the following components by weight: 0.8 to 1.2 kg of nano silicon dioxide, 2.0 to 2.5 kg of hydroxypropyl methylcellulose and 0.6 to 1.0 kg of zinc diricinoleate. The powder is dried at low temperature, so that the degradation rate of beta-lactam rings is reduced, the stability of amoxicillin is improved, and the bioavailability of the medicine is improved.

Intumescent composition comprising an acid donor (A), a carbon donor (B), a binder polymer (C) and a blowing agent (D). The acid donor (A) is selected from the group consisting of ammonium polyphosphate, ammonium dihydrogen phosphate, ethylenediamine phosphate, ammonium pentaborate, guanylurea phosphate, diguanidine phosphate and mixtures thereof. The carbon donor (B) is selected from the group consisting of glucose, arabinose and other monosaccharides, lactose, maltose and other disaccharides, starch, cellulose, dextrin and other polysaccharides, sorbitol, erythritol, pentaerythritol, dipentaerythritol, mannitol and other polyhydric alcohols and mixtures thereof. The blowing agent is provided in the form of microsphere particles comprising a thermoplastic polymer shell encapsulating a propellant, which microsphere particles are expandable microspheres.

The present application relates to a kind of toughened heat-resistant full biodegradable polylactic acid packaging material and its preparation method.Polylactic acid, PBAT, corn starch, stearic acid starch ester, mannitol, epoxy-terminated PBAT-PLA block oligomer, PDLA grafted white carbon black and processing aid are dried, premixed plasticized, melt reaction blending, extruded and granulated and formed, to obtain packaging material.Epoxy-terminated PBAT-PLA block oligomer improves interface compatibility and toughening, PDLA grafted white carbon black promotes crystallization and stereocomplex crystal formation, and both synergistically improve material toughness, impact resistance, heat resistance and hot water dimensional stability.

The present disclosure provides a method of reducing, preventing or treating an intestinal infection, preventing or treating a disease associated with protozoan parasite of the genus Eimeria, inhibiting an oocyst sporulation of a protozoan parasite or preventing a sporozoite invasion or reproduction, preventing or treating coccidiosis, promoting growth performance, controlling, treating and / or preventing necrotic enteritis in a subject, comprising administering to the subject an effective amount of a composition comprising a Crassocephalum rabens (CR), a bioactive extract thereof (CRE), an active ingredient(s) contained in a CR (CR_API) or CRE (CRE_API), a combination of two or more of a CR, a CRE, a CR_API and a CRE_API, or one or more of a-linolenic acid, citric acid, lactic acid, mannitol, palmitic acid, aspartic acid and 1-monomyristin.

The invention relates to the field of functional additives for daily chemicals, and particularly discloses hydrolyzed procyanidine freeze-dried powder and a preparation method thereof. The hydrolyzed procyanidine freeze-dried powder is prepared by freeze-drying and comprises the following raw materials in parts by weight: 0.1-0.2 part of hydrolyzed procyanidine, 25-35 parts of carnosine, 10-20 parts of a stabilizer, 0.1-0.3 part of acetyl hexapeptide-8 and 45-55 parts of water. The stabilizer is selected from at least one of mannan, trehalose, mannitol, cane sugar, betaine, whey protein, PVP (Polyvinyl Pyrrolidone), PEG (Polyethylene Glycol), glycine, histidine, leucine, sodium alginate, beta-cyclodextrin, maltodextrin and chitosan. The hydrolyzed procyanidine freeze-dried powder has good storage stability, can keep activity for a long time, is still stable after being dissolved in water for a long time, and has less activity loss.

The invention discloses a refreshing pill and a preparation method thereof, and particularly relates to the technical field of refreshing products. The refreshing pill comprises an outer coating and an inner core, the outer coating comprises 28% of sorbitol, 12% of xylitol, 20% of gum base, 10% of maltitol, 1% of edible flavors and fragrances, 1% of glycerin, 2% of D-mannitol, 5% of Arabic gum, 7% of sucralose, 2% of phospholipid, 2% of palm wax and 2% of shellac, and the inner core is hard edible particles. The inner core is composed of 4% of a refreshing substance and 4% of cane sugar and is used for refreshing people. According to the refreshing pill and the preparation method thereof, through combination of natural components, the refreshing effect is achieved, and meanwhile potential adverse effects on the body are reduced.

The invention discloses a soluble microneedle composition for improving sleep and a microneedle and application of the soluble microneedle composition, and belongs to the technical field of medical care, the soluble microneedle composition comprises a needle tip section composition and a substrate composition, comprising 1%-70% of dexmedetomidine or a salt thereof, 1.5%-10% of glycerin, 1.5%-15% of mannitol and the balance of water. The substrate composition is an aqueous solution of a high-molecular compound. The soluble microneedle composition for improving sleep provided by the invention can prevent dexmedetomidine or a salt thereof from diffusing in a microneedle product, so that carried drugs are concentrated at a needle tip part, a technical support is provided for effective transmission of active components and accurate sustained and controlled release drug delivery, and quantitative drug delivery of dexmedetomidine or a salt thereof is realized.

The invention discloses an ophthalmic preparation and application thereof. The ophthalmic preparation comprises a TNF alpha nano antibody, a protective agent, a thickening agent, a buffer solution and an optional surfactant, and pH lt is larger than or equal to 6.0 and smaller than or equal to 0; 7, 7; the protective agent is selected from at least one of trehalose, mannitol, arginine and glycine; the thickening agent is selected from any one of hydroxypropyl methyl cellulose, polyvinyl alcohol and sodium hyaluronate; the buffer solution is a phosphate buffer solution or a histidine buffer solution. The ophthalmic formulations are useful in the treatment of immune-mediated inflammatory ophthalmic diseases.